Field Medical Inc., a pioneer in cardiac pulsed field ablation (PFA) technology, today announced the successful closing of ...

Boston Scientific reports positive outcomes from the ADVANTAGE AF trial’s second phase, assessing the Farapulse and Farapoint ...

Boston Scientific Corporation (NYSE: BSX) today announced positive 12-month primary endpoint results from the second phase of ...

During the first 3 months following the ablation procedure (known as the blanking period), any occurrence of AF/atrial tachycardia was not considered a late recurrence. Additionally, episodes of ...

Catheter Ablation Devices for Atrial Fibrillation Market 2035, Driven by advanced devices, better clinical outcomes, and rising regulatory approvals.

the hazard ratio of a first recurrence of any atrial tachyarrhythmia -- atrial fibrillation, flutter, or tachycardia -- lasting at least 30 seconds during the period from day 91 to day 365 after the ...

(PACE 2011; 34:414–421) Atrial tachycardia (AT ... [1–6] These forms of AT can be cured by radiofrequency ablation (RFA). To simplify the procedure and reduce the x-ray exposure time, accurate ...

Boston Scientific Corporation today announced positive 12-month primary endpoint results from the second phase of the ...

Boston Scientific (NYSE: BSX) today announced positive 12-month study results for its Farapulse pulsed field ablation (PFA) ...

Field Medical secures major funding to reimagine life-saving cardiac care through next-gen ablation therapies.

The FieldForce™ Ablation System is an investigational device and is limited by federal (or United States) law to investigational use. The Growing Prevalence of VT and AF Ventricular tachycardia (VT) ...